CADTH has received notices of pending submissions from BioMarin for galsulfase (Naglazyme) for patients with mucopolysaccharidosis type VI and from Amgen for denosumab (Xgeva) for the prevention of skeletal-related events due to bone metastases from solid tumours.  For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website. Note that typically only patient groups may submit input; however, there is currently a pilot process for receiving patient input submissions from individual patients and caregivers.

For more details, go to: https://www.cadth.ca/cdr/patient-input/open-calls-for-patient-input/cdr-patient-input-submission?brand_name=Naglazyme&generic_name=Galsulfase%20%28Drug%20Plan%20Submission%29&indicator=Mucopolysaccharidosis%20VI